FDA Approves Zomig Nasal Spray for Migraine for Ages 12 and Up
Impax announced that the Food and Drug Administration (FDA) has approved Zomig (zolmitriptan) Nasal Spray for use in pediatric patients aged ≥12 years for the acute treatment of migraine with or without aura.
The approval was based on safety and efficacy data from clinical trials, which demonstrated that Zomig Nasal Spray 5 mg was significantly more effective in providing no headache pain, relief of headache, and other associated symptoms of migraine when treating migraine in pediatric patients compared to placebo.
Zomig Nasal Spray, a selective 5-HT1B/1D receptor agonist, is already indicated for the acute treatment of migraine with or without aura in adults. It is available in 2.5-mg and 5-mg single-use nasal spray units.
Enjoying our content?
Thanks for visiting Clinical Pain Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Clinical Pain Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.